← All trials
NCT04120415
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2019
- Primary completion
- Jun 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 69
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of FranceLead sponsor
- CHU Henri MondorCollaborator
- Erasmus University RotterdamCollaborator
- University of ParisCollaborator
- University of HamburgCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy director
- University of LiverpoolCollaborator
- Medical Research CouncilCollaborator
- European CommissionCollaborator
- Institut d'Investigacions Biomèdiques August Pi i SunyerCollaborator
- University of BarcelonaCollaborator
- University of LausanneCollaborator
- EuroVacc FoundationCollaborator
- Imperial College LondonCollaborator
- Government of SwitzerlandCollaborator
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniCollaborator
- European AIDS Treatment Group (EATG)Collaborator
- University of LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.